Thermo Fisher Scientific Inc. $TMO Shares Purchased by Eagle Global Advisors LLC

Key Points

• Eagle Global Advisors LLC increased its stake in Thermo Fisher Scientific by 69.2%, bringing its total holdings to 36,369 shares valued at approximately $14.7 million.
• The company's most recent earnings report showed $5.36 EPS and revenue of $10.86 billion, both exceeding analyst expectations, with a 2.9% year-over-year revenue increase.
• Thermo Fisher Scientific declared a quarterly dividend of $0.43 per share, with a payout ratio of 9.95%, scheduled for payment on October 15th.

Eagle Global Advisors LLC boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 69.2% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 36,369 shares of the medical research company's stock after acquiring an additional 14,870 shares during the quarter. Eagle Global Advisors LLC's holdings in Thermo Fisher Scientific were worth $14,746,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in TMO. GAMMA Investing LLC lifted its holdings in Thermo Fisher Scientific by 60,610.9% in the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock valued at $1,203,859,000 after purchasing an additional 2,415,346 shares in the last quarter. Nuveen LLC purchased a new position in Thermo Fisher Scientific in the 1st quarter valued at $532,360,000. Sarasin & Partners LLP purchased a new position in Thermo Fisher Scientific in the 1st quarter valued at $242,991,000. EdgePoint Investment Group Inc. purchased a new position in Thermo Fisher Scientific in the 1st quarter valued at $172,139,000. Finally, Cohen Investment Advisors LLC lifted its holdings in Thermo Fisher Scientific by 6,655.5% in the 1st quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company's stock valued at $167,271,000 after purchasing an additional 331,180 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Up 1.1%

Shares of TMO opened at $464.18 on Friday. The firm has a market cap of $175.28 billion, a P/E ratio of 26.85, a price-to-earnings-growth ratio of 2.49 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $623.77. The company's 50-day moving average price is $476.70 and its 200 day moving average price is $448.02. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.Thermo Fisher Scientific's revenue was up 2.9% compared to the same quarter last year. During the same period in the previous year, the company posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's payout ratio is currently 9.95%.

Analyst Ratings Changes

TMO has been the topic of a number of research reports. Robert W. Baird raised their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Hsbc Global Res lowered Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. William Blair assumed coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They set an "outperform" rating on the stock. UBS Group lifted their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a report on Thursday, July 24th. Finally, HSBC reiterated a "hold" rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $588.35.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares of the company's stock, valued at $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.